The unwinding related section 1902(e)(14) strategies newly available to Medicaid and CHIP agencies can provide significant relief to states facing pending eligibility and enrollment actions and processing delays, workforce and systems limitations, and other operational challenges. Ensuring eligible individuals do not lose coverage for procedural or administrative reasons and supporting those who are ineligible for Medicaid/CHIP transition to Marketplace coverage will be paramount for all states as they begin to resume normal operations when the federal public health emergency (PHE) ends. This expert perspective outlines the time-limited targeted enrollment flexibilities that CMS has availed to states through section 1902(e)(14) waiver authority and discusses considerations beyond the strategies described in federal guidance and supplemental resources.
The SUPPORT Act: New Tools in Medicaid to Address the Opioid Epidemic
Every day, an average of more than 115 Americans die from an opioid overdose, reflecting a crisis that has evolved – but not dissipated. Following several months of bipartisan, bicameral hearings, markups, and negotiations about how to address the opioid epidemic, the Senate on October 3 passed H.R. 6, The Substance Use Disorder Prevention that Promotes Opioid Recovery and Treatment for Patients and Communities Act (the “SUPPORT Act”). On October 25, President Trump signed the legislation. On November 16, State Health and Value Strategies hosted a webinar, with technical experts from Manatt Health, on the SUPPORT Act. Most stakeholders agree that the bill is a significant step forward in addressing the opioid epidemic, reflecting a range of important policy changes such as initiatives to increase access to medication-assisted treatment (MAT), new grant, pilot and demonstration projects, and a series of changes to Medicaid and Medicare. During this webinar, experts from Manatt Health reviewed major health provisions of the new law and implications for states.